Category: ACADIA

  • Acadia puts blame on FDA as Nuplazid rejected for dementia

    Acadia Pharmaceuticals is butting heads with US regulators again, this time over the FDA’s decision to reject its Nuplazid (pimavanserin) for use in dementia-related psychosis (DRP) – with the company bemused by the agency’s apparent pivot on an agreed trial design.  The FDA has rejected the expansion of the drug – originally approved to treat […]

  • ACADIA Acquires CerSci Therapeutics for $52.5M

    Shots: ACADIA acquires all outstanding shares of CerSci for $52.5M. CerSci may receive up to $887M as development, commercialization milestones along with royalties on sales The acquisition will boost ACADIA’s clinical pipeline with the addition of non-opioid pain therapies including CerSci’s lead candidate ACP-044 ACP-044 has demonstrated a promising effect in the P-I study with an […]